Pharming Group NV (PHAR): Price and Financial Metrics
GET POWR RATINGS... FREE!
PHAR POWR Grades
- PHAR scores best on the Growth dimension, with a Growth rank ahead of 0% of US stocks.
- PHAR's strongest trending metric is Growth; it's been moving down over the last 28 days.
- PHAR's current lowest rank is in the Growth metric (where it is better than 0% of US stocks).
PHAR Stock Summary
- With a one year PEG ratio of 4.36, Pharming Group NV is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 15.13% of US stocks.
- PHAR's went public 0.94 years ago, making it older than just 0.38% of listed US stocks we're tracking.
- With a year-over-year growth in debt of 68.98%, Pharming Group NV's debt growth rate surpasses 88.2% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Pharming Group NV are SRGA, TDW, UAMY, POAI, and LIVN.
- To check out Pharming Group NV's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001828316.
PHAR Stock Price Chart Interactive Chart >
PHAR Price/Volume Stats
| Current price | $7.94 | 52-week high | $21.99 |
| Prev. close | $8.03 | 52-week low | $7.94 |
| Day low | $7.94 | Volume | 1,458 |
| Day high | $8.12 | Avg. volume | 6,359 |
| 50-day MA | $9.26 | Dividend yield | N/A |
| 200-day MA | $11.72 | Market Cap | 513.58M |
Pharming Group NV (PHAR) Company Bio
Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.
Latest PHAR News From Around the Web
Below are the latest news stories about Pharming Group NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.
Buy These 2 Stocks Before They Jump Over 100%, Says OppenheimerWhat happens when headwinds meet tailwinds? In meteorology, head-on collisions of opposite air masses gives birth to thunderstorms; add some Coriolis force, and the storm becomes cyclonic. As historian Bruce Catton once described such action, in a political context, ‘tornado weather: sultriest and most menacing.’ But it seems, for now, that we’ve missed that bullet. As Oppenheimer’s chief investment strategist John Stoltzfus writes, “While economic data continues to show persistently high levels of inflation attributable to supply chain shocks as well as labor shortages, more people are returning to work and demand for services has increased. |
Pharming Group (NASDAQ:PHAR) Reaches New 12-Month Low at $8.25Pharming Group (NASDAQ:PHAR) reached a new 52-week low during trading on Thursday . The stock traded as low as $8.25 and last traded at $8.25, with a volume of 24 shares trading hands. The stock had previously closed at $9.61. Separately, Zacks Investment Research raised shares of Pharming Group from a sell rating to a [] |
Pharming Group N.V.: Pharming Group reports financial results for the first nine months of 2021Patient enrollment and product demand driving ongoing revenue recovery to US$52.9 million in Q3 2021 Operating profit impacted by upfront payment of US$ 13.1 million for the in-licensing of OTL-10 |
Pharming Group NV (PHGUF) to Report Q3 Results: What Awaits?Pharming Group NV (PHGUF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Pharming Group reports financial results for the first nine months of 2021Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021. |
PHAR Price Returns
| 1-mo | -11.78% |
| 3-mo | N/A |
| 6-mo | -35.02% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -47.75% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...